1104 related articles for article (PubMed ID: 21939718)
1. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
2. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
3. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
4. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
6. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
8. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
9. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
10. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
11. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.
Chen CY; Liu HJ; Tsai CP; Chung CY; Shih YS; Chang PC; Chiu YT; Hu YC
Vaccine; 2010 Nov; 28(48):7644-51. PubMed ID: 20883735
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
13. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
17. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
18. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.
Vajdy M; Baudner B; Del Giudice G; O'Hagan D
Clin Immunol; 2007 May; 123(2):166-75. PubMed ID: 17349825
[TBL] [Abstract][Full Text] [Related]
19. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
20. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
